InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
October 20, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease, as demonstrated in a mouse model. According to the announcement, the research was conducted as part of a sponsored agreement with Columbia […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact
October 18, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Continues Focus to Create the Best Psychedelic Therapies for Patients
October 17, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Safety Evaluation Study of Its Novel Time-Released Ketamine Formulation
October 10, 2022
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate at Upcoming Dawson James Small Cap Growth Conference
October 6, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include […]
Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market
October 5, 2022
Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Notes WIPO Publication of International PCT Patent Application
October 4, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that the World Intellectual Property Organization (“WIPO”) published its international patent application: PCT/IB2022/052347. Titled “Improved Methods for the Use of Psychedelics,” the PCT application covers the intravenous administration of psilocybin and psilocin and […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package
October 3, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering
September 30, 2022
Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of […]
InvestorNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Stands Distinct with Integrated Approach to Reduce Noise, Bridge Silos
September 29, 2022
Cerberus Sentinel (NASDAQ: CISO) is helping organizations create a culture of security, allowing them to quantify, define and capture a return on investment from information technology and cybersecurity spending. “Cerberus Sentinel has established a reputation for its integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. The […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expands Insurance Coverage with Medicare for Ketamine Therapy Patients
September 29, 2022
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has become one of a few U.S.-based ketamine therapy providers to offer Medicare coverage to patients at eight KWC clinics across the country. Under Medicare, KWC is accepting a limited number […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering
September 27, 2022
Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio
September 26, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC, VA-CCN Collaborate to Expand Access to SPRAVATO(R) Treatments
September 22, 2022
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded its partnership with the Veterans Administration Community Care Network (“VA-CCN”) to cover SPRAVATO(R) treatments at select clinics. VA-CCN patients experiencing treatment-resistant depression with prior authorization from the VA-CCN will […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose
September 20, 2022
First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) […]
MindSite News Launches Live Conversation Series on Psychedelics and Mental Health
September 20, 2022
MindSite News Launches Live Conversation Series on Psychedelics and Mental Health OAKLAND, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) — MindSite News—the only news site dedicated exclusively to reporting on mental health in America—is launching a live public conversation series that will take place throughout the month of October to engage the public in conversations about psychedelics […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
September 19, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim O’Neill as its chief financial officer. In the new role, O’Neill, who brings over 30 years of experience as a […]
Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Building Reputation as Industry Leader in Cybersecurity, Compliance Services
September 19, 2022
Recent report notes a significant increase in cyber incidents CISO is dedicated to “pulling disparate technologies, teams and vendors together to help clients simplify and accelerate their journey to cyber resilience” Cerberus Sentinel works closely with clients to integrate compliance and security into an organization-wide culture of cybersecurity Considering what the government calls “a growing […]
InvestorNewsBreaks – Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
September 15, 2022
Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
September 14, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
September 13, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that it has retained IMS Investor Relations. According to the announcement, IMS will work with Tryp Therapeutics to provide capital markets consulting, corporate communications and investor outreach. Specifically, IMS and Tryp will work together […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research
September 8, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Present at H.C. Wainwright Annual Global Investment Conference
September 8, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that CEO Matt Stang will be participating in the 24th annual H.C. Wainwright Annual Global Investment Conference. The three-day event is scheduled for Sept. 12–14, 2022. During his presentation, Stang will provide a summary of […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Makes Top-100 Innovation List, Company Postpones Meet Delic Event
September 7, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Matt Stang was included in World Biz magazine’s Top-100 CEOs in Innovation for 2022. The announcement noted that Stang was recognized as a champion of creativity who is dedicated to making a positive environmental and social impact. Stand cofounded Delic Corp., which has grown into a […]
Dawson James Securities Announces October Date for 7th Annual Small Cap Growth Conference
September 6, 2022
JUPITER, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Dawson James Securities, Inc. (“Dawson”), a full-service boutique investment banking firm focused on emerging growth companies since 2004 and committed to helping clients navigate the healthcare, biotechnology and technology markets, today announces its 7th Annual Dawson James Small Cap Growth Conference. The event will take place on […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
August 31, 2022
A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
August 30, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical […]
IBN (InvestorBrandNetwork) Coverage Initiated for Cerberus Cyber Sentinel Corp.
August 30, 2022
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Cerberus Cyber Sentinel Corp. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, today announces it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities. Cerberus Sentinel leverages an integrated approach to reduce noise […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector
August 26, 2022
Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain’s connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research
August 25, 2022
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients […]
InvestorNewsBreaks – Why Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Is ‘One to Watch’
August 25, 2022
Cerberus Sentinel (NASDAQ: CISO), an industry leader in managed cybersecurity and compliance services, leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. “Pulling disparate technologies, teams and vendors together, Cerberus helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
August 17, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), along with Clinilabs Drug Development Corporation, has been granted a Schedule I license from the U.S. Drug Enforcement Agency (“DEA”) to support the first-in-human phase 1/2a clinical trial of its proprietary CYB003. The DEA license required in order for a company […]
Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF
August 17, 2022
Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Key Management Positions
August 16, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, have announced advanced appointments for two key executives. According to the company, Delic Holdings cofounder and CEO Matt Stang has been named executive chair while COO Kevin Nicholson has been named CEO and will also join […]
Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Is ‘One to Watch’
August 16, 2022
Cerberus Sentinel shares were listed on the Nasdaq in the first quarter of 2022 The company joined the broad-market Russell 2000 Index in June 2022 Cerberus Sentinel posted a 376% revenue CAGR for the years 2019 through 2021 In 2021, 58% of the company’s revenue was recurring revenue from managed services contracts Cerberus Sentinel has […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Subsidiary Acquires Mineral Rights in Core Development Areas in Montana
August 15, 2022
Laredo Oil (OTC: LRDC), an oil exploration and production company, through its wholly owned subsidiary Lustre Oil Company LLC, is acquiring mineral rights in northeastern Montana core development areas. According to the company, the company has increased its acreage in these key locations from 24,000 net acres to 45,246 gross and 37,932 net acres currently. […]
InvestorNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data
August 12, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report
August 9, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes
August 4, 2022
Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, […]
Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain
August 3, 2022
Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain […]